Shares of ANI Pharmaceuticals (ANIP) surged 17.03% in pre-market trading on Friday following the company's announcement of record second-quarter 2025 financial results and an upward revision of its full-year 2025 guidance. The strong performance and optimistic outlook have sparked significant investor enthusiasm, driving the stock's substantial gain.

ANI Pharmaceuticals reported a Q2 2025 adjusted earnings per share (EPS) of $1.80, handily beating the analyst estimate of $1.39. The company's Q2 revenue reached $211.371 million, surpassing the expected $187.797 million. This impressive performance demonstrates ANI's strong market position and effective execution of its business strategy across its rare disease, brands, and generics portfolios.

Key highlights from the quarterly results include: - Record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% - Rare Disease quarterly net revenues of $104.0 million, including Cortrophin Gel net revenues of $81.6 million, an increase of 66.0% year-over-year - Generics quarterly net revenues of $90.3 million, an increase of 22.1% year-over-year - Record quarterly adjusted non-GAAP EBITDA of $54.1 million, an increase of 62.8% year-over-year

Adding to the positive sentiment, ANI Pharmaceuticals significantly raised its full-year 2025 guidance. The company now expects net revenues in the range of $818-$843 million, up from previous estimates of $768-$793 million and exceeding the analyst consensus of $791.5 million. Additionally, the adjusted EPS outlook for 2025 has been increased to $6.98-$7.35, surpassing the previous guidance of $6.27-$6.62 and the analyst estimate of $6.53.

Nikhil Lalwani, President and CEO of ANI, commented on the results: "We had another record-setting quarter for our Company, with all-time highs in net revenue, adjusted EBITDA, and adjusted EPS, reflecting very strong momentum across our business units. Our Rare Disease team delivered exceptional sequential and year-over-year quarterly growth with Cortrophin Gel, driving prescription demand and new patient starts to new highs."

The company's strong performance was driven by growth across multiple segments, including its rare disease portfolio, generics business, and brands. The success of Cortrophin Gel, ANI's lead rare disease asset, and the expansion of its generics business through new product launches and operational excellence have contributed significantly to the company's robust financial results.